GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non-drug care up front.
|Articles|July 5, 2012
ACOs Already in Place Gain Momentum
Advertisement
Uncertainty did not stop health systems from racing ahead with accountable care as the U.S. Supreme Court debated the healthcare reform law that launched Medicare's efforts to encourage the emerging model.
Now that the law survived largely intact, the industry's accountable care experimentation will give efforts structure and momentum, executives said.
Read the full story:
Source: ModernHealthcare.com
“We are pleased that the Supreme Court has released their decision because now we know the context in which we move forward,” Chuck Mooty, interim CEO for Minneapolis-based Fairview Health Services, said in a statement.
Advertisement
Related to this article
This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.
Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
GLP-1 RAs Improve MASLD, MASH Markers, but Long-Term Benefits Unclear
4
Health Equity & Access Weekly Roundup: November 6, 2026
5